Table 1. Ibrutinib cohort with sequential visits for signaling studies.

Patients	TP-0903 [LD50 (μM)]	Axl Expression (%)	Months on Ibrutinib
P1	ND	ND	0
	>0.500	90.11	6
	>0.500	80.83	9
	0.144	88.82	18
P2	ND	ND	0
	>0.500	83.06	2
	0.125	83.26	12
P3	ND	ND	0
	0.15	83.84	3
	0.2219	59.4	6
P4	ND	ND	0
	0.166	43.81	1
	ND	ND	2
P5	ND	ND	0
	>0.500	20.4	8
	>0.500	20.59	12
	>0.500	4.66	14
	>0.500	7.45	16
	>0.500	6.5	22
	>0.500	16.61	23
	>0.500	18.54	27
P8	ND	ND	0
	0.469	24.03	7
	ND	ND	11
P12	ND	ND	0
	>0.500	67.47	9
	0.313	74.18	14
P6	ND	ND	Before Progression
	ND	ND	20 (at progression)
	0.375	42.92	21 (at progression)
	0.0875	40.48	23 (at progression)

“0” indicates time point before ibrutinib treatment started.

ND: Not done (flow or drug sensitivity); used for Western blot and PCR analyses only.

Important: Samples were selected for study on the basis of enough available primary fresh cells.